{
  "response": {
    "text": "Based on the information available, here's the answer to your questions:\n\n*   **Ingredient starting with \"G\" in a potentially more effective regime within clinical trial NCT00262769:** While the specifics of the \"more effective regime\" within the NCT00262769 trial are not detailed in the search results, **Glatiramer acetate** is an ingredient starting with the letter \"G\" that is used for treating multiple sclerosis\n*   **Exclusivity date for Glatiramer acetate:** The FDA designated Glatiramer acetate as an orphan drug on 11/09/1987 and approved it for marketing on 12/20/1996, with an exclusivity end date of **12-20-2003**.\n",
    "citations": []
  }
}